European Council for
Cardiovascular Research

Covid-19 and the renin-angiotensin system

Bavishi et al. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. 2020 Apr 3. doi: 10.1001/jamacardio.2020.1282. https://www.ncbi.nlm.nih.gov/pubmed/32242890

Sommerstein et al. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1. https://www.ncbi.nlm.nih.gov/pubmed/32233753

Chen et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020 Mar 30. pii: cvaa078. doi: 10.1093/cvr/cvaa078. https://www.ncbi.nlm.nih.gov/pubmed/32227090

Zhang F The potential risk of kidney vulnerable to novel coronavirus 2019 infection. Am J Physiol Renal Physiol. 2020 Mar 30. doi: 10.1152/ajprenal.00085.2020. https://www.ncbi.nlm.nih.gov/pubmed/32223555

Li et al. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension. Hypertens Res. 2020 Mar 30. doi: 10.1038/s41440-020-0433-1. https://www.ncbi.nlm.nih.gov/pubmed/32231220

Meng et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020 Dec;9(1):757-760. doi: 10.1080/22221751.2020.1746200. https://www.ncbi.nlm.nih.gov/pubmed/32228222

Marin et al. Facts and reflections on COVID-19 and anti-hypertensives drugs. Drug Discov Ther. 2020 Mar 26. doi: 10.5582/ddt.2020.01017. https://www.ncbi.nlm.nih.gov/pubmed/32213760